PONTE VEDRA, Fla., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, Inc. (collectively, "Stryker") (NYSE: SYK), alleging infringement of 9 patents ...

PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies at the American Orthopaedic Foot & Ankle Societ ...

Treace Medical Concepts Inc (NASDAQ:TMCI) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations John Treace - Founder & CEO Mark Hair - Chief Financial Officer Conference Call Participants Lilia-Celine Lozada - JPMorgan Danielle Antalffy - UBS Drew Ranieri - Morgan Stanley Iseult McMahon - BTIG Benjamin Goldstein - Truist Securities Harrison Parsons - Stephens Operator Good day, and thank you for standing by. Welcome to the Treace Medical Conce ...

Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.24%. A quarter ago, it was expected that this orthopedic medical device maker would post a loss of $0.30 per share when it actually produced a loss of $0.30, delivering no surprise. Over the last four quarters ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (State or o ...

Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2024 Financial Results PONTE VEDRA, Fla. – August 6, 2024 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights • Revenue of $44.5 million in ...

PONTE VEDRA, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue of $44.5 million in second quarter 2024 increased 6% over same period in 2023 Gross margin ...

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company's investor relations website at https://investors.treace.com/. Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. ...

PONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Truist Securities MedTech Conference on Tuesda ...

NEW YORK, May 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ: TMCI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Treace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 7, 2024 ...